Quantcast

Latest Oncolytic virus Stories

2010-11-04 18:07:35

New research could lead to improved vaccines for cancerous tumors Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed. New research, published today in the journal Science, reveals that a type of stromal cell found in many cancers which expresses fibroblast activation protein alpha (FAP), plays a major role in suppressing the immune...

2010-10-26 06:30:00

CALGARY, Oct. 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN((R)) in patients with metastatic colorectal cancer prior to surgical resection of liver metastases was presented at the International Symposium on Cytotoxic T-lymphocytes (CTL) and Immunostimulation being held in Pamplona, Spain. The presentation...

2010-10-21 08:00:00

SAN FRANCISCO, Oct. 21 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today announced the appointment of Mark P. Backer, Ph.D., to the newly-created position of senior vice president, technical operations. Dr. Backer will be responsible for all aspects of chemistry, manufacturing and controls (CMC) in support of Jennerex's late-stage product, JX-594, as well as pipeline products. "We are extremely pleased to welcome...

2010-10-18 12:05:50

Terminal metastatic cancer "“ the presently untreatable cause of the great majority of all cancer deaths "“ has now been effectively treated in three common fatal cancers in mice, according to announced Genomic Systems, citing research published online in the Proceedings of the National Academy of Sciences (PNAS). Research conducted by Robert J. Debs, M.D., senior scientist at the California Pacific Medical Center Research Institute in collaboration with four other laboratories...

2010-09-28 06:30:00

CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent, # 7,803,385 entitled "Reoviruses Having Modified Sequences." The patent claims cover methods for making and using modified reoviruses, and pharmaceutical compositions that include modified reoviruses. "This composition of matter patent covers the reovirus variant that Oncolytics is using in its clinical trials with patent protection...

2010-09-13 06:00:00

SAN FRANCISCO and MONTREAL, Sept. 13 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada. "While these data...

2010-09-08 01:00:00

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the...

cd8dad27a479baca8c6739d65503785a1
2010-08-25 14:27:11

Study suggests potential for new oncolytic therapies A novel mechanism used by adenovirus to sidestep the cell's suicide program, could go a long way to explain how tumor suppressor genes are silenced in tumor cells and pave the way for a new type of targeted cancer therapy, report researchers at the Salk Institute for Biological Studies in the Aug. 26, 2010 issue of Nature. When a cell is under stress, the tumor suppressor p53 springs into action activating an army of foot soldiers that...

2010-08-19 06:00:00

SAN FRANCISCO, Aug. 19 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million. Proceeds from this transaction will be used to advance the Company's oncology product platform, led by JX-594, a novel oncolytic agent...

2010-07-07 15:52:30

Scientists have used a genetically reprogrammed herpes virus and an anti-vascular drug to shrink spreading distant sarcomas designed to model metastatic disease in mice "“ still an elusive goal when treating humans with cancer, according to a study in the July 8 Gene Therapy. Less than 30 percent of patients with metastatic cancer survive beyond five years, despite the aggressive use of modern combination therapies, including chemotherapy. This creates a significant need for new sarcoma...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related